149
Participants
Start Date
December 30, 2014
Primary Completion Date
September 3, 2019
Study Completion Date
September 3, 2019
RO6958688
RO6958688 is given as an intravenous (IV) infusion as a single administration in Part I, and QW, Q3W, or as a combined QW/Q3W step up dosing regimen (cycle = 7 days in the QW regimen and cycle = 21 days in the Q3W regimen) in Part II of the study.
Obinutuzumab
Obinutuzumab is given as an IV infusion at a dose level of 2000 mg on Day -13 or 1000 mg on Days -13 and -12 prior to the treatment start with RO6958688 on Cycle 1 Day 1.
Tocilizumab
Tocilizumab will be administered as an IV infusion as necessary to treat adverse events.
Rigshospitalet; Onkologisk Klinik, København Ø
Columbia University Medical Center, New York
START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid
Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid
START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid
Medical University of South Carolina, Charleston
Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona
Sarah Cannon Cancer Center, Germantown
Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica, Siena
Centre Leon Berard; Departement Oncologie Medicale, Lyon
University Of Colorado, Aurora
IRCCS IST. Tumori Fondaz. Pascale; S.C. Oncologia Medica,Melanoma,Immunoterapia E Terapie Innovative, Napoli
Cedars Sinai Medical Center; Samuel-Oschin Comprehensive Cancer Institute, Los Angeles
UCLA Cancer Center, Santa Monica
Stanford University, Palo Alto
Yale Cancer Center; Medical Oncology, New Haven
Dana Farber - Harvard, Boston
Princess Margaret Cancer Center, Toronto
Antoni van Leeuwenhoek Ziekenhuis, Amsterdam
Hospital del Mar; Servicio de Oncologia, Barcelona
Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona
Hoffmann-La Roche
INDUSTRY